Webinar Summary:

Drug discovery research is a complex endeavor that involves multiple stages. By providing the initial set of compounds with the potential to be developed, the hit identification phase, lays the groundwork for the next phases and significantly influences the success of the entire drug development process.

High-Throughput Screening (HTS) revolutionized drug discovery and was shown to be one of the most powerful tools for hit identification. However, an HTS campaign “per se” is typically not sufficient to support the selection and prioritization of the chemical matter identified. Therefore, focused follow-up activities become crucial for choosing the most promising hits.

In this webinar, we will focus on our “HIT QUALIFICATION” strategy as an effective and fundamental tool to unlock the true value of hits derived from HTS campaigns run in Axxam. We will talk about how biology and chemistry expertise can melt together to ensure a comprehensive validation, optimization, and prioritization of the best-suited molecules, thus enhancing the probability of downstream success and maximizing the value of this early yet impactful phase of drug discovery research.  

Keywords:

Drug discovery; Hit identification; High-Throughput Screening (HTS); Integrated research; Hit qualification; Hit selection; Medicinal chemistry.

Speakers:

• Angela Molteni, Head of HTS automation , Axxam

• Iolanda Micco, Head of Discovery chemistry, Axxam